Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial-Reference-Cited by-同舟云学术

Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial

Published:2018-11 Issue: Volume:104 Page:160-168
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Hurvitz S.A.^ORCID,Quek R.G.W.,Turner N.C.,Telli M.L.,Rugo H.S.,Mailliez A.,Ettl J.,Grischke E.,Mina L.A.,Balmaña J.,Fasching P.A.,Bhattacharyya H.,Hannah A.L.,Robson M.E.^ORCID,Wardley A.M.^ORCID

Funder

Pfizer Inc

Pfizer

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference20 articles.

1. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years;Malone;Cancer Res,2006

2. PARP inhibitors: synthetic lethality in the clinic;Lord;Science,2017

4. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial;Oza;Lancet Oncol,2018

5. PARP inhibitors and quality of life in ovarian cancer;Aoki;Lancet Oncol,2018

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Update Breast Cancer 2024 Part 1 – Expert Opinion on Advanced Breast Cancer;Geburtshilfe und Frauenheilkunde;2024-05-29

2. Effect of Ruai-Sanyin formula maintenance therapy after completion of standard adjuvant treatment on survival in women with early-stage triple negative breast cancer: A multicenter prospective cohort study;2023-01-16

3. Current Therapeutic Strategies for Metastatic Triple-Negative Breast Cancer: From Pharmacists’ Perspective;Journal of Clinical Medicine;2022-10-12

4. Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival;Cancers;2022-09-23

5. Effect of Ruai-Sanyin formula maintenance therapy after completion of standard adjuvant treatment on survival in women with early-stage triple negative breast cancer: A multicenter prospective cohort study;2022-09-23